Weekly berobenatide study for adults in China with overweight or obesity
Compares weekly berobenatide with placebo in adults with excess weight.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Key facts
- Where
- Beijing, Changchun, Changzhou, Chongqing, Hangzhou, Harbin, Hefei, Hengshui, Huizhou, Huzhou, Jinan, Luoyang, Nanchang, Nanjing, Nantong, Ningbo, Pingxiang, Shanghai, Shijiazhuang, Shiyan, Tianjin, Wuhan, Xi'an, Zhengzhou, and Zhenjiang, ChinaSee the 34 sites
- Phase
- Phase 3
Where in China
- Beijing Friendship HospitalBeijing, ChinaTaking people
- Beijing Pinggu HospitalBeijing, ChinaTaking people
- Beijing Tsinghua Changgung HospitalBeijing, ChinaTaking people
- Peking University People's HospitalBeijing, ChinaTaking people
- The Second Hospital of Jilin UniversityChangchun, ChinaTaking people
- Changzhou Second People's HospitalChangzhou, ChinaTaking people
- Chongqing People's HospitalChongqing, ChinaTaking people
- Chongqing University Three Gorges HospitalChongqing, ChinaTaking people
- Hangzhou First People's HospitalHangzhou, ChinaNot yet recruiting
- The Fourth Hospital of Harbin Medical UniversityHarbin, ChinaTaking people
- The Second People's Hospital of HefeiHefei, ChinaTaking people
- Harrison International Peace HospitalHengshui, ChinaTaking people
- Huizhou Central People's HospitalHuizhou, ChinaTaking people
- Huzhou Central HospitalHuzhou, ChinaTaking people
- Jinan Central HospitalJinan, ChinaTaking people
- Luoyang First People's HospitalLuoyang, ChinaTaking people
- The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang, ChinaTaking people
- Jiangxi Provincial People's HospitalNanchang, ChinaTaking people
- Nanjing First HospitalNanjing, ChinaTaking people
- The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaTaking people
- Affiliated Hospital of Nantong UniversityNantong, ChinaTaking people
- The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaTaking people
- Pingxiang People's HospitalPingxiang, ChinaTaking people
- Pudong New Area People's Hospital ShanghaiShanghai, ChinaTaking people
- Shanghai Tenth People's HospitalShanghai, ChinaNot yet recruiting
- The Fifth People's Hospital of ShanghaiShanghai, ChinaTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
- The Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaNot yet recruiting
- Shiyan Taihe HospitalShiyan, ChinaNot yet recruiting
- Tianjin Medical University General HospitalTianjin, ChinaTaking people
- Wuhan Third HospitalWuhan, ChinaTaking people
- The First Affiliated Hospital of Xi'an Medical UniversityXi'an, ChinaTaking people
- The Second Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaTaking people
- Affiliated Hospital of Jiangsu UniversityZhenjiang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07792954
- Record updated
- 5 November 2026
- Original description
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.Read full original descriptionShow less
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY PF-08653944 IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.
The purpose of this study is to learn whether berobenatide is safe and effective for adults in China who have overweight or obesity. Researchers will compare berobenatide with a placebo, which looks like the study treatment but does not contain active medicine.
People may be able to participate if they are adults with obesity or if they have overweight together with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment.
Participants will be randomly assigned to receive either berobenatide or placebo. The study treatment will be administered according to the study protocol, and participants will be monitored throughout the study to assess changes in body weight and overall health, as well as any side effects that may occur.
During participation, participants will attend study visits and complete study-related assessments. Researchers will collect information about participants' health, body weight, and safety throughout the study. Details about the number of visits, study duration, and study procedures will be explained by the study team before participation.
The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.
Inclusion: Adults ≥18 years of age; BMI ≥28 kg/m²; or BMI ≥24 kg/m² and <28 kg/m² with at least one weight-related comorbidity; Participants with T2D must have HbA1c 6.5% to 10.0%; At least one prior unsuccessful dietary weight-loss attempt.
Exclusion: Recent bariatric surgery or obesity procedures; Type 1 diabetes mellitus; History of pancreatitis; Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2); Significant recent weight change (>5% within 3 months); Pregnancy or breastfeeding.